Analysts think CTMX stock price could increase by 842%
Apr 07, 2025, 11:25 AM
110.04%
What does CTMX do
CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
6 analysts think CTMX stock price will increase by 842.39%. The current median analyst target is $4.33 compared to a current stock price of $0.46. The lowest analysts target is $3.28 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
